RTTNews转述Rapport股价创52周高并复述RAP-219已进入3期

Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology company developing precision medicines for neurological and psychiatric disorders, has touched a new 52-week high of $52.83 in today's trading session.
The stock has risen sharply over the past year, supported by continued clinical progress for its lead candidate RAP-219.
RAP-219 has advanced into Phase 3 development for focal onset seizures, with the FOCUS 1 and FOCUS 2 trials now enrolling patients.
The company is also preparing to expand development into primary generalized tonic-clonic seizures, with a Phase 3 trial planned for the first half of 2027.
RAP-219 Clinical Progress:
Rapport's Phase 2a data continued to support the potential of RAP-219, with the therapy demonstrating sustained seizure reductions during an additional eight-week follow-up period.
Median reductions in clinical seizures reached 90% during weeks 9-12 and 59% during weeks 13-16 compared with baseline.
The company now estimates RAP-219's half-life at approximately 22 days, up from its previous estimate of 14 days, based on pharmacokinetic data and population PK modeling.
Rapport also initiated an open-label long-term safety study, with initial data expected in the fourth quarter of 2026.
Additional Pipeline Updates:
The company's Phase 2 trial of RAP-219 in bipolar mania remains on track to deliver topline results in October 2026.
Rapport has modified the statistical analysis plan and increased enrollment, potentially allowing the study to serve as confirmatory evidence of effectiveness.
The company is also advancing a long-acting injectable formulation of RAP-219, with initial Phase 1 pharmacokinetic data expected in 2027.
Rapport's RAP-641, an a6ß4 nicotinic acetylcholine receptor agonist, continues to advance through IND-enabling studies as a potential non-opioid treatment for chronic pain and migraine.
Q2 Financial Results:
Rapport reported a net loss of $56.6 million for the second quarter of 2026, compared with a loss of $26.7 million in the prior-year period.
Research and development expenses increased to $51.4 million from $22.7 million, primarily reflecting higher clinical development and pipeline costs. Selling, general and administrative expenses rose to $9.4 million from $6.8 million.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled $436.1 million, excluding restricted cash.
The company expects its cash position to fund operations and capital requirements into the second half of 2029.
RAPP closed Wednesday's session at $52.50, up 2.60%, after reaching an intraday high of $52.83. The stock's 52-week range is approximately $14.11 to $52.83.
Currently the stock is trading at $51.00, down 2.86%
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.